摘要
目的 观察分析对失代偿性心衰患者实施钙离子增敏剂左西孟旦治疗的临床效果和应用价值。方法 采用回顾性研究方法，选择院内就诊的120例失代偿性心衰患者（样本纳入例数：120例；样本纳入时间：2023年1月—2024年1月），以随机摸球为基础分组方式，分为对照、实验两个小组，观察例数高度一致。分别实施常规治疗，钙离子增敏剂左西孟旦治疗。收集分析治疗效果。结果 与对照组（常规治疗）相比，实验组（左西孟旦治疗）治疗后的血清学指标（BNP、cTnI）更低，生活质量评分（角色功能/情绪功能/认知功能/社会功能/躯体功能）更高，实验组治疗后的心功能指标（LVEF更高，LVEDD更低）优于对照组，差异均具有统计学意义（P<0.05）。结论 左西孟旦治疗可以有效改善血清学水平，促进失代偿性心衰患者心功能恢复，提高生活质量，有较高应用价值。
关键词： 钙离子增敏剂；失代偿性心衰；左西孟旦；治疗效果
Abstract
Objective To observe and analyze the clinical effect and application value of calcium sensitizer levosimendan in the treatment of patients with decompensated heart failure. Methods A retrospective study was conducted to select 120 patients with decompensated heart failure (sample number: 120; Sample inclusion time: January 2023 - January 2024) was divided into control and experimental groups based on random ball touching, and the number of observed cases was highly consistent. Conventional treatment and calcium sensitizer levosimendan were respectively administered. The therapeutic effect was collected and analyzed. Results Compared with the control group (conventional treatment), the serological index (BNP, cTnI) of the experimental group (levosimendan treatment) after treatment was lower, the quality of life score (role function/emotional function/cognitive function/social function/physical function) was higher, and the cardiac function index (higher LVEF, lower LVEDD) of the experimental group after treatment was better than that of the control group. The differences were statistically significant (P<0.05). Conclusion Levosimendan treatment can effectively improve the serological level, promote the recovery of cardiac function and improve the quality of life in patients with decompensated heart failure, and has high application value.
Key words： Calcium ion sensitizer; Decompensated heart failure; Levosimendan; Therapeutic effect
参考文献 References
[1] 杨振.益气活血法对老年气虚血瘀型失代偿期慢性心力衰竭患者心功能及血清NT-proBNP、CysC的影响[J].心血管病防治知识（学术版）,2023,13(9):28-30
[2] 贾妍,张瑞宁,黄柳,等.冻干重组人脑利钠肽联合芪苈强心胶囊序贯治疗对急性失代偿性心力衰竭患者疗效及心功能的影响[J].心脑血管病防治,2021,21(6):577-579591
[3] 郑伟.钙离子增敏剂治疗慢性心力衰竭患者的效果及对血浆心肌损伤相关指标表达的影响[J].中国医学创新,2021, 18(26):35-39
[4] 王牛牛,鲁大胜,杨卿青,等.沙库巴曲缬沙坦和盐酸贝那普利对急性失代偿性心力衰竭患者血清NT-proBNP cTnT水平和心脏超声功能指标的影响[J].河北医学,2023,29(5): 861-866
[5] 何雅芬,曾又晓,黄雪娥.沙库巴曲缬沙坦钠与雷米普利治疗老年急性失代偿心力衰竭合并肺动脉高压患者的效果比较[J].中外医学研究,2023,21(28):19-22
[6] 房晓伟,张小玲,王翠翠.钙离子增敏剂治疗慢性心力衰竭失代偿患者的临床疗效和安全性观察[J].河北医学,2018, 24(10):1659-1664
[7] 杨艳.左西孟旦治疗射血分数保留心力衰竭老年患者效果分析[J].社区医学杂志,2019,17(5):273-275279
[8] 黄春华.左西孟旦联合多巴酚丁胺治疗急性失代偿心力衰竭患者的效果[J].中国民康医学,2024,36(6):20-22
[9] 王丽辉,姜晶.左昔孟旦联合托伐普坦治疗急性失代偿性心力衰竭患者的疗效观察[J].中国卫生标准管理,2024,15(11): 114-117
[10] 梁雁丽.托伐普坦联合左西孟旦治疗急性失代偿性心力衰竭患者的效果[J].中国民康医学,2024,36(6):17-19
[11] 章礼玲,顾崇怀,乔锐,等.维立西呱对急性失代偿心衰的疗效及对不同LVDd患者LVEF的影响[J].中国药房,2024, 35(11):1374-1379
[12] 张岩,高辉,张玉,等.左西孟旦联合沙库巴曲缬沙坦钠对老年急性失代偿性心力衰竭患者心功能、血清sST2、sCD40L及预后的影响[J].华北理工大学学报（医学版）,2023,25(2): 107-112
[13] 王艳丽.丹参多酚酸盐联合多索茶碱治疗慢性肺源性心脏病失代偿期患者的效果[J].中国民康医学,2024,36(5):93-96
[14] 胡乐义,周姝,程景林,等.左西孟旦治疗急性失代偿性心力衰竭患者的短期疗效和安全性观察[J].河北医学,2023, 29(10): 1725-1730.